Clarivate Analytics, a global company providing insights and analytics, announced that it published a new report called “Pharmaceutical innovation in the APAC region: A quantitative company ranking and future outlook.”
The report provides insights on which countries/regions in the Asia-Pacific region are most conducive to innovation, which companies lead the way today or are poised to lead tomorrow, and how a company’s innovation profile affects its success. Report findings show, while exhibiting strong drug development capability, greater early stage partnering and increased academic collaboration are needed for companies in the APAC region to expand their global footprint.
Of the 929 companies studied across 14 countries/regions in APAC, there are 5,893 drugs in active development and 1,549 that have been launched. Japan, due to its market maturity, has the highest innovation score across all three innovation indices, with China and South Korea positioned as strong contenders for the most innovative country. Japan, China and Korea alone account for 80% of drugs in active development.
View or download the full report here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.